Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21847058 | 0.89 | ALDH1A1 (0.46) | KDM4EALDH1A1SSTR4P2RX4SIGMAR1 | |
| SCHEMBL21816599 | 0.88 | KDM4E (0.44) | KDM4EALDH1A1SSTR4P2RX4SSTR1 | |
| Cyclohexanol SCHEMBL9329942 | 0.87 | KDM4E (0.51) | KDM4EALDH1A1SIGMAR1EPHX2EPHX1 | |
| SCHEMBL1749205 | 0.87 | SSTR4 (0.44) | KDM4EALDH1A1SSTR4SSTR1 | |
| SCHEMBL1189936 | 0.87 | SSTR4 (0.44) | KDM4EALDH1A1SSTR4SSTR1 | |
| SCHEMBL4202085 | 0.87 | SSTR4 (0.44) | KDM4EALDH1A1SSTR4SSTR1 | |
| Hydrochloric Acid SCHEMBL2013502 | 0.85 | SSTR4 (0.43) | KDM4EALDH1A1SSTR4SSTR1 | |
| SCHEMBL13621156 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1SSTR4P2RX4SIGMAR1 | |
| SCHEMBL25387824 | 0.82 | PKM (0.43) | KDM4EALDH1A1SSTR4P2RX4SSTR1 | |
| SCHEMBL508551 | 0.82 | ATM (0.45) | KDM4EALDH1A1SSTR4P2RX4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | claimed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | claimed |
| EP-3666268-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT Pharmaceuticals, LLC (US) | 2020-06-17 | — | — | EP | claimed |
| EP-3609888-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| EP-3233071-B1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS LLC (US) | 2019-09-18 | — | — | EP | claimed |
| WO-2018170182-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2018-09-20 | — | — | WO | claimed |
| US-20180251443-A9 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, LLC | 2018-09-06 | — | — | US | claimed |
| US-20180208573-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | BOYD, MICHAEL R. | 2018-07-26 | — | — | US | claimed |
| US-20180044314-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS INC (US) | 2018-02-15 | — | — | US | claimed |
| EP-3233794-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| WO-2016100542-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| WO-2016100546-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | claimed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | claimed |
| EP-1515724-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-10-21 | — | — | EP | claimed |
| CN-100421665-C | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-10-01 | — | — | CN | claimed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | claimed |
| CN-1898234-A | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORP (US) | 2007-01-17 | — | — | CN | claimed |
| CN-1674906-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2005-09-28 | — | — | CN | claimed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | KDM4E 1585/4885ALDH1A1 989/4885SSTR4 1562/4885 |
| US-20180251443-A9 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | KRAS, NRAS, HRAS | KDM4E 4194/4885ALDH1A1 1984/4885SSTR4 4464/4885 |
| US-20180208573-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | KDM4E 1762/4885ALDH1A1 769/4885SSTR4 1657/4885 |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP2, MMP14 | KDM4E 1350/4885ALDH1A1 497/4885SSTR4 3720/4885 |
| US-20180044314-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | KRAS, NRAS, HRAS | KDM4E 4194/4885ALDH1A1 1984/4885SSTR4 4464/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | KDM4E 1839/4885ALDH1A1 415/4885SSTR4 3760/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | KDM4E 1350/4885ALDH1A1 497/4885SSTR4 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.